Kamada (NASDAQ:KMDA) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• Kamada reported $0.13 EPS for the quarter, exceeding analyst expectations of $0.09 EPS by $0.04.
• The company updated its fiscal year 2025 guidance, although it reported a significant difference between actual revenue of $44.75 million and expected revenue of $158.59 million.
• Shares of Kamada increased by 0.7% on trading day, with a market cap of $422.70 million and a recent price-to-earnings ratio of 21.62.

Kamada (NASDAQ:KMDA - Get Free Report) issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.04, Zacks reports. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada updated its FY 2025 guidance to EPS.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded down $0.27 during mid-day trading on Wednesday, hitting $6.97. 94,971 shares of the company traded hands, compared to its average volume of 48,883. The firm has a market cap of $400.84 million, a P/E ratio of 20.50, a PEG ratio of 0.77 and a beta of 0.93. Kamada has a 52-week low of $5.17 and a 52-week high of $9.15. The firm's 50 day simple moving average is $7.47 and its 200 day simple moving average is $7.07.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Kamada during the 1st quarter worth approximately $582,000. Goldman Sachs Group Inc. acquired a new position in shares of Kamada in the 1st quarter worth approximately $497,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Kamada in the 2nd quarter worth approximately $472,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kamada in the 1st quarter worth approximately $206,000. Finally, Jump Financial LLC acquired a new position in shares of Kamada in the 2nd quarter worth approximately $219,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KMDA. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Benchmark reissued a "buy" rating and issued a $15.00 price target on shares of Kamada in a research note on Thursday, May 15th. Finally, Sidoti upgraded Kamada to a "hold" rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Kamada has a consensus rating of "Moderate Buy" and a consensus target price of $13.00.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.